An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.